Drug intelligence / Profile preview

Oviget

Development stage: Unknown
Lead developer: SBM Enterprises
Modality: Small Molecules
Administration: Oral

Overview

Oviget is a branded generic antibiotic formulation containing ofloxacin, a second-generation fluoroquinolone. It is marketed by SBM Pharmaceuticals (SBM Enterprises) as a 200mg tablet. Ofloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase (Type II topoisomerase) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. It is indicated for the treatment of various bacterial infections, including respiratory tract, urinary tract, and skin infections.

Brand names: OvigetOviget-200Oviget200Oviget 200
Other names: ofloxacin

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on Oviget.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oviget.

Explore the full profile